Related by context. Frequent words. (Click for all words.) 77 submitted Marketing Authorization 74 submitted Biologics License 67 Application MAA 62 FDA Accepts 60 IND Investigational New 58 Marketing Authorization 57 supplemental Biologics License Application 57 Marketing Authorisation 57 Crucell NV Euronext 56 Application BLA 56 NASDAQ CRXL 56 Mutual Recognition Procedure 55 Marketing Authorization Application MAA 55 R sorafenib tablets 55 PRIALT 55 Australian Therapeutic Goods 55 Marketing Authorization Application 55 refractory chronic lymphocytic 54 Loramyc R 54 Orphan Drug status 54 Positive Opinion 54 Clofarabine 54 Scientific Advice 54 CryoSeal FS System 54 Pivotal Trial 54 Alitretinoin 53 Nexavar ® 53 Ingenuity Pathways Analysis 53 Swissmedic 53 Orphan Drug designation 53 Telavancin 53 NASDAQ SHPGY 53 Ceftobiprole 53 Medicinal Products EMEA 53 Application 53 Develop Novel 52 LYON France BUSINESS WIRE 52 Pivotal Phase III 52 Market Approval PMA 52 ZALBIN 52 orphan medicinal product 52 PRNewswire FirstCall BioMarin Pharmaceutical 52 Panzem R 52 RNAi Therapeutics 52 Orphan Drug Status 51 Inc. Nasdaq SEPR 51 Nasdaq ENZN 51 Office InfoPath 51 Loramyc ® 51 Belimumab 51 Toctino R 51 Nasdaq REGN 51 Investigational Device Exemption 51 Fast Track Designation 51 OTCQX RHHBY 51 dalbavancin 51 Pirfenidone 51 Idera Pharmaceuticals 51 Golimumab 51 HAYWARD Calif. BUSINESS WIRE 51 AVEO Pharmaceuticals 51 Maraviroc 51 Adobe LiveCycle 51 Inc. Nasdaq IMGN 51 Alvesco 51 daptomycin 50 Angiox 50 Euro MTF market 50 Product Characteristics 50 orphan designation 50 SCHWARZ PHARMA 50 Inc Therapeutic Competitors 50 FIRAZYR 50 optical biosensors 50 Delivers Enhanced 50 Digital Signatures 50 ILOG Rules 50 Icatibant 50 Achieves Milestone 50 Cimzia ® 50 Malaria Vaccine 50 Workflow Solution 50 Fluidigm Corporation 50 Application Programming Interface 50 Multiple Vulnerabilities 50 Clevudine 50 Ambrisentan 50 Orphan Drug 49 Milnacipran 49 Ixempra 49 Automation Platform 49 human antithrombin 49 Account Transfer 49 SUMAVEL DosePro 49 Vimovo 49 alvimopan 49 application 49 PRNewswire FirstCall Cell Therapeutics 49 Exalgo 49 TYGACIL 49 Zalbin